Skip to main content

Advertisement

Log in

Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Chidamide (CS055/HBI-8000) is a new histone deacetylase (HDAC) inhibitor of the benzamide class currently under clinical development in cancer indications. This study reports the in vitro and in vivo antitumor characteristics of the compound.

Methods

Selectivity and potency of chidamide in inhibition of HDAC isotypes were analyzed by using a panel of human recombinant HDAC proteins. Tumor cell lines either in culture or inoculated in nude mice were used for the evaluation of the compound’s antitumor activity. To investigate the immune cell-mediated antitumor effect, isolated peripheral blood mononuclear cells from healthy donors were treated with chidamide, and cytotoxicity and expression of relevant surface proteins were analyzed. Microarray gene expression studies were performed on peripheral white blood cells from two T-cell lymphoma patients treated with chidamide.

Results

Chidamide was found to be a low nanomolar inhibitor of HDAC1, 2, 3, and 10, the HDAC isotypes well documented to be associated with the malignant phenotype. Significant and broad spectrum in vitro and in vivo antitumor activity, including a wide therapeutic index, was observed. Chidamide was also shown to enhance the cytotoxic effect of human peripheral mononuclear cells ex vivo on K562 target cells, accompanied by the upregulation of proteins involved in NK cell functions. Furthermore, the expression of a number of genes involved in immune cell-mediated antitumor activity was observed to be upregulated in peripheral white blood cells from two T-cell lymphoma patients who responded to chidamide administration.

Conclusions

The results presented in this study provide evidence that chidamide has potential applicability for the treatment of a variety of tumor types, either as a single agent or in combination therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Khan AU, Krishnamurthy S (2005) Histone modifications as key regulators of transcription. Front Biosci 10:866–872

    Article  PubMed  CAS  Google Scholar 

  2. Graham JS, Kaye SB, Brown R (2009) The promises and pitfalls of epigenetic therapies in solid tumours. Eur J Cancer 45:1129–1136

    Article  PubMed  CAS  Google Scholar 

  3. Inoue S, Mai A, Dyer MJ, Cohen GM (2006) Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumour necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 66:6785–6792

    Article  PubMed  CAS  Google Scholar 

  4. Nakagawa M, Oda Y, Eguchi T, Aishima S, Yao T, Hosoi F, Basaki Y, Ono M, Kuwano M, Tanaka M, Tsuneyoshi M (2007) Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 18:769–774

    PubMed  CAS  Google Scholar 

  5. Weichert W, Röske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M, Kristiansen G (2008) Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 98:604–610

    Article  PubMed  CAS  Google Scholar 

  6. Park JH, Kim SH, Choi MC, Lee J, Oh DY, Im SA, Bang YJ, Kim TY (2008) Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. Biochem Biophys Res Commun 368:318–322

    Article  PubMed  CAS  Google Scholar 

  7. Paris M, Porcelloni M, Binaschi M, Fattori D (2008) Histone deacetylase inhibitors: from bench to clinic. J Med Chem 51:1505–1529

    Article  PubMed  CAS  Google Scholar 

  8. Noureen N, Rashid H, Kalsoom S (2010) Identification of type-specific anticancer histone deacetylase inhibitors: road to success. Cancer Chemother Pharmacol 66(4):625–633

    Article  PubMed  CAS  Google Scholar 

  9. FDA (2006) US Food and Drug Administration, Center for Drug Evaluation and Research, Office of Oncology Drug Products (OODP). Approval letter for ZOLINZA, NDA 21-991, Merck and Co. Inc. 6 Oct 2006

  10. FDA (2009) US Food and Drug Administration, Center for Drug Evaluation and Research, Office of Oncology Drug Products (OODP). Approval letter for ISTODAX, NDA 022393, Gloucester Pharmaceuticals. 5 Nov 2009

  11. FDA (2011) US Food and Drug Administration, Center for Drug Evaluation and Research, Office of Oncology Drug Products (OODP). Approval letter for ISTODAX, NDA 022393/S-004, Celgene Corporation. 16 Jun 2011

  12. Xie AH, Li BY, Liao CZ, Li ZB, Lu XP, Shi LM, Zhou JJ (2004) Docking study of HDAC: implication for benzamide inhibitors binding mode. Acta Phys-Chim Sin 20:569–572

    CAS  Google Scholar 

  13. Xie AH, Liao CZ, Li ZB, Ning ZQ, Hu W, Lu XP, Shi LM, Zhou J (2004) Quantitative structure-activity relationship study of histone deacetylase inhibitors. Curr Med Chem Anticancer Agents 4:273–299

    Article  PubMed  CAS  Google Scholar 

  14. Yin ZH, Wu ZW, Lan YK, Liao CZ, Shan S, Li ZL, Ning ZQ, Lu XP, Li ZB (2004) Synthesis of chidamide, a new histone deacetylase (HDAC) inhibitor. Chin J New Drugs 13:536–538

    CAS  Google Scholar 

  15. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, Nakanishi O (1999) A synthetic inhibitor of histone deacetylase, MS-27–275, with marked in vivo antitumor activity against human tumors. PNAS 96:4592–4597

    Article  PubMed  CAS  Google Scholar 

  16. Hess-Stumpp H, Bracker TU, Henderson D, Politz O (2007) MS-275, a potent orally available inhibitor of histone deacetylases-the development of an anticancer agent. Int J Biochem Cell Biol 39:1388–1405

    Article  PubMed  CAS  Google Scholar 

  17. Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget MC, Kalita A, Liu J, Lu AH, Zhou NZ, Robert MF, Gillespie J, Wang JJ, Ste-Croix H, Rahil J, Lefebvre S, Moradei O, Delorme D, Macleod AR, Besterman JM, Li Z (2008) MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumour activity in vitro and in vivo. Mol Cancer Ther 7:759–768

    Article  PubMed  CAS  Google Scholar 

  18. Park BL, Kim YJ, Cheong HS, Lee SO, Han CS, Yoon JH, Park JH, Chang HS, Park CS, Lee HS, Shin HD (2007) HDAC10 promoter polymorphism associated with development of HCC among chronic HBV patients. Biochem Biophys Res Commun 363:776–781

    Article  PubMed  CAS  Google Scholar 

  19. Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38–51

    Article  PubMed  CAS  Google Scholar 

  20. Munshi A, Kurland JF, Nishikawa T, Tanaka T, Hobbs ML, Tucker SL, Ismail S, Stevens C, Meyn RE (2005) Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 11:4912–4922

    Article  PubMed  CAS  Google Scholar 

  21. Qiang L, Xiao H, Campos EI, Ho VC, Li G (2005) Development of a PAN-specific, affinity-purified antiacetylated lysine antibody for detection, identification, isolation, and intracellular localization of acetylated protein. J Immunoass Immunochem 26:13–23

    Article  CAS  Google Scholar 

  22. Beckers T, Burkhardt C, Wieland H, Gimmnich P, Ciossek T, Maier T, Sanders K (2007) Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer 121:1138–1148

    Article  PubMed  CAS  Google Scholar 

  23. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS, Sehested M (2008) Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 409:581–589

    Article  PubMed  CAS  Google Scholar 

  24. Skov S, Pedersen MT, Andresen L, Straten PT, Woetmann A, Odum N (2005) Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res 65:11136–11145

    Article  PubMed  CAS  Google Scholar 

  25. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, Steinle A, Salih HR (2005) Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 65:6321–6329

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was partially supported by grants from the Chinese National “863” Project (2008AA02Z303), National Prize for Small- and Middle-sized enterprises (04C26214420752), the Significant Project in Biotech Field from Guangdong Province (2003A10903) and Shenzhen City (2005-K2-009). The authors thank K. Zhang and J.-Z. Zhu at Chipscreen Biosciences for their technical support. The authors also thank Dr. Jason C. Wong from Roche R&D Center China for the critical review of the manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Xian-Ping Lu.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 52 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ning, ZQ., Li, ZB., Newman, M.J. et al. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol 69, 901–909 (2012). https://doi.org/10.1007/s00280-011-1766-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-011-1766-x

Keywords

Navigation